This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Investor Alert: Upcoming Deadlines In Shareholder Litigation Involving Teva Pharmaceuticals And Tri-Tech Holdings, Inc.

Holzer & Holzer reminds investors of upcoming deadlines for applications to serve as lead plaintiff in securities class action lawsuits against Teva Pharmaceuticals Industries Limited and Tri-Tech Holdings, Inc.

Teva Pharmaceuticals Industries Limited

A class action lawsuit has been filed on behalf of investors who purchased Teva (NYSE: TEVA) securities between January 1, 2012 and October 29, 2013. The complaint alleges, among other things, that Teva made false and misleading statements to investors during that time that failed to disclose significant disagreements between the company’s board of directors and senior management. On October 30, 2013, Teva’s CEO and President, Dr. Jeremy Levin, announced his resignation from the company sending the price of Teva stock down significantly.

The deadline to seek appointment as lead plaintiff in this lawsuit, which is pending in the United States District Court for the Southern District of New York, is February 24, 2014.

If you purchased shares between January 1, 2012 and October 29, 2013 and would like more information about your rights, please contact the firm or visit

Tri-Tech Holdings, Inc.

A class action lawsuit has been filed on behalf of investors who purchased Tri-Tech Holdings (NASDAQ: TRIT) securities between March 26, 2012 and December 12, 2013 alleging the company violated the federal securities laws by issuing false and misleading statements to investors. According to the complaint, the company lacked adequate internal controls rendering certain of its statements made during that time misleading. On December 12, 2013, it was revealed that the company’s former Chief Executive Officer was terminated due to alleged violations of the company’s policies on wire transfers and the Nasdaq halted trading of TRIT following an 11% decline in share price.

The deadline to seek appointment as lead plaintiff in this lawsuit, which is pending in the United States District Court for the Southern District of New York, is February 18, 2014. More information about the lawsuit and the firm are available at

Investors Are Encouraged To Contact The Firm

Investors that suffered significant losses investing in either of these companies during the specified times who are interested in potentially serving as lead plaintiff in the respective class actions are encouraged to contact Marshall P. Dees, Esq. by email at or via toll-free telephone at (888) 508-6832 to discuss their legal rights.

A lead plaintiff is a representative party appointed by the court to act on behalf of other class members in directing the litigation. Any member of the purported class may move the court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $95.03 0.21%
FB $116.73 0.00%
GOOG $691.02 0.00%
TSLA $249.50 0.72%
YHOO $36.59 0.00%


Chart of I:DJI
DOW 17,830.76 -210.79 -1.17%
S&P 500 2,075.81 -19.34 -0.92%
NASDAQ 4,805.2910 -57.85 -1.19%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs